

# Vincenzo Di Lauro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4862415/publications.pdf>

Version: 2024-02-01

20  
papers

626  
citations

1039406

9  
h-index

713013

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma.. Journal of Clinical Pathology, 1997, 50, 30-32.	1.0	142
2	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	5.1	91
3	TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Letters, 1998, 124, 73-78.	3.2	88
4	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 6479.	1.8	71
5	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 4579.	1.8	66
6	Targeting Autophagy in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7836.	1.8	54
7	Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study. Tumori, 2004, 90, 285-288.	0.6	33
8	Angiogenesis and Tumor Growth. New England Journal of Medicine, 1996, 334, 920-921.	13.9	22
9	Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Annals of Oncology, 2000, 11, 1041-1044.	0.6	16
10	Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2012, 83, 422-431.	2.0	6
11	Combined chemoimmunotherapy of metastatic melanoma: a single institution experience. Melanoma Research, 2005, 15, 209-212.	0.6	5
12	Trastuzumab and Vinorelbine as Highly Effective and Safe Therapy for HER-2-Overexpressing Metastatic Breast Cancer. A Single Institution Experience. Tumori, 2008, 94, 464-468.	0.6	5
13	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 2019, 120, 959-967.	2.9	5
14	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
15	Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series. Journal of Oncology, 2012, 2012, 1-6.	0.6	4
16	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma. Anti-Cancer Drugs, 2019, 30, 959-963.	0.7	2
17	Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience. Tumori, 2008, 94, 464-8.	0.6	2
18	Anti-EGFR target therapy in advanced thymic epithelial tumors.. Journal of Clinical Oncology, 2019, 37, 8567-8567.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study. <i>Oncotarget</i> , 2021, 12, 221-229.	0.8	0
20	CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12532-e12532.	0.8	0